Reports of increased mortality and GH: Will this affect current clinical practice?

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 2, 2012, Pages 380-383

  Malozowski, Saul ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

CANCER RISK; CAUSE OF DEATH; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; EDITORIAL; GROWTH HORMONE DEFICIENCY; HUMAN; MEDICAL DECISION MAKING; MORTALITY; PRIORITY JOURNAL; PROVOCATION TEST; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; SHORT STATURE;

FEMALE; GROWTH DISORDERS; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; MALE;

EID: 84856785051     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3363     Document Type: Editorial

References (12)

1. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kagueildou F, Rey G, Coste J 2012 Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 97:416-425
2. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ 1999 Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341:785-792 (Pubitemid 29420473)
3. Tauber M, Diene G, Molinas C, Hébert M 2008 Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet A 146:881-887 (Pubitemid 351499792)
4. The Diabetes Control and Complications Trial Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
5. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr RH, Probstfield JL, Simons-Morton DG, Friedewald WT 2008 Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559 (Pubitemid 351831356)
6. Unger EF, Thompson AM, Blank MJ, Temple R 2010 Erythropoiesis-stimulating agents-time for a reevaluation. N Engl J Med 362: 189-192
7. Kimmel PL, Malozowski S 2010 Reevaluating erythropoiesis-stimulating agents. N Engl J Med 362:1742-1743
8. Mills JL, Schonberger LB, Wysowski DK, Brown P, Durako SJ, Cox C, Kong F, Fradkin JE 2004 Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr 144:430-436 (Pubitemid 38457343)
9. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA 2006 Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 91:3494-3498 (Pubitemid 44402126)
10. Sävendahl L 2011 On behalf of all SAGhE investigators in Europe Safety and Appropriateness of Growth Hormone in Europe (SAGhE): update. Horm Res Suppl 2:534
11. Melmed S 2006 Acromegaly. N Engl J Med 355:2558-2573 (Pubitemid 44917504)
12. Sandberg DE 2011 Psychosocial aspects of short stature and its management: good deeds require good science. Horm Res Paediatr 76(Suppl 3):37-39